Recombinant Humanized monoclonal antibody expressed in CHO binding to Human CCR2. MLN1202 is a humanized monoclonal antibody with high specificity to CCR2, which interrupts MCP-1 binding to CCR2. MLN1202 is being developed for the treatment of immune mediated diseases.
Figure 1 Mean serum concentrations of MLN1202 per dose group over time.
Arrows indicate the times of intravenous infusion with MLN1202. Serial samples were assessed on the days of infusion, and single samples were assessed on the other days.
Vergunst, C. E., Gerlag, D. M., Lopatinskaya, L., Klareskog, L., Smith, M. D., Van den Bosch, F., ... & Baeten, D. (2008). Modulation of CCR2 in rheumatoid arthritis: a double‐blind, randomized, placebo‐controlled clinical trial. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 58(7), 1931-1939.
Figure 2 Mean occupancy rates of CCR2 on peripheral blood monocytes per dose group over time.
Rates were first calculated per patient as a percentage increase in occupied CCR2 receptors as compared with that before the first infusion with MLN1202. Free CCR2 decreased significantly (P<0.001) in all MLN1202-treated groups. CCR2 blockade in the 1.5 mg/kg and 4.0 mg/kg groups was demonstrated by a mean decrease of free CCR2 over 43 days of 86% and 94%, respectively
Vergunst, C. E., Gerlag, D. M., Lopatinskaya, L., Klareskog, L., Smith, M. D., Van den Bosch, F., ... & Baeten, D. (2008). Modulation of CCR2 in rheumatoid arthritis: a double‐blind, randomized, placebo‐controlled clinical trial. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 58(7), 1931-1939.
Figure 3 Relationship between mean MLN1202 serum concentration and pharmacodynamic response expressed as the change in mean equivalent of soluble fluorescence (MESF) in the Mu1D9 free-site assay.
A reduction in the MESF indicates a reduction in free CCR2 on peripheral blood monocytes. The oval shape indicates the serum concentration range (trough levels included) attained using the 2 highest dose levels of MLN1202 from day 1 through day 43; boldface values with arrows show the point at which 90% of the total MESF response (indicating CCR2 receptor saturation) was achieved.
Vergunst, C. E., Gerlag, D. M., Lopatinskaya, L., Klareskog, L., Smith, M. D., Van den Bosch, F., ... & Baeten, D. (2008). Modulation of CCR2 in rheumatoid arthritis: a double‐blind, randomized, placebo‐controlled clinical trial. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 58(7), 1931-1939.
Figure 4 Dose-dependent increase in serum levels of the CCR2 ligand, CCL2, in MLN1202-treated patients.
Results are the mean and SD fold increase from day 1 (d1) pretreatment. The absolute pretreatment (day 1) serum levels were comparable between all 4 patient groups (P=0.97). The increase in CCL2 was statistically significant in the 2 highest dose level groups when compared with that in the placebo group; however, the difference between the 2 highest dose level groups did not reach statistical significance.
Vergunst, C. E., Gerlag, D. M., Lopatinskaya, L., Klareskog, L., Smith, M. D., Van den Bosch, F., ... & Baeten, D. (2008). Modulation of CCR2 in rheumatoid arthritis: a double‐blind, randomized, placebo‐controlled clinical trial. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 58(7), 1931-1939.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-159 | Recombinant Anti-human CCR2 Antibody | WB, IF, FuncS | IgG |
MHH-159 | Recombinant Human Anti-human CCR2 Antibody | WB, IP, FuncS | IgG |
MRO-0264-CN | Rabbit Anti-CCR2 Recombinant Antibody (clone CBACN-101) | WB, IHC, IP, FC | Rabbit IgG |
HPAB-1571WJ | Human Anti-CCR2 Recombinant Antibody (clone hu1D9) | ELISA, WB | Human IgG2a |
VS3-CJ941 | Rabbit Anti-CCR2 Recombinant Antibody (VS3-CJ941) | WB, IHC, IP, FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-159-F(E) | Recombinant Anti-human CCR2 Antibody Fab Fragment | FC, ELISA, FuncS | Fab |
HPAB-0247-YC-F(E) | Human Anti-CCR2 Recombinant Antibody; Fab Fragment (HPAB-0247-YC-F(E)) | ELISA, FC | Human Fab |
HPAB-0248-YC-F(E) | Human Anti-CCR2 Recombinant Antibody; Fab Fragment (HPAB-0248-YC-F(E)) | ELISA, FC | Human Fab |
HPAB-0249-YC-F(E) | Human Anti-CCR2 Recombinant Antibody; Fab Fragment (HPAB-0249-YC-F(E)) | ELISA, FC | Human Fab |
HPAB-1571WJ-F(E) | Human Anti-CCR2 Recombinant Antibody; Fab Fragment (clone hu1D9) | ELISA, WB | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-1508CL-F(E) | Human Anti-CCR2 Recombinant Antibody; Fab Fragment (TAB-1508CL-F(E)) | FuncS | Human Fab |
TAB-1509CL-F(E) | Human Anti-CCR2 Recombinant Antibody; Fab Fragment (TAB-1509CL-F(E)) | FC | Human Fab |
TAB-1510CL-F(E) | Human Anti-CCR2 Recombinant Antibody; Fab Fragment (TAB-1510CL-F(E)) | FC | Human Fab |
TAB-1511CL-F(E) | Human Anti-CCR2 Recombinant Antibody; Fab Fragment (TAB-1511CL-F(E)) | ELISA | Human Fab |
TAB-1512CL-F(E) | Human Anti-CCR2 Recombinant Antibody; Fab Fragment (TAB-1512CL-F(E)) | ELISA, FC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
BRD-0096MZ | Chicken Anti-CCR2 Polyclonal IgY | WB | Chicken antibody |
BRD-0127MZ | Chicken Anti-CKR2 Polyclonal IgY | WB | Chicken antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0520 | Hi-Affi™ Rabbit Anti-CCR2 Recombinant Antibody (clone DS520AB) | WB, FC, IP, IHC-Fr, IHC-P | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-444CQ | Anti-Human CCR2 Recombinant Antibody (Plozalizumab) | ELISA, IHC, FC, IP, IF, Inhib | IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0247-YC-S(P) | Human Anti-CCR2 Recombinant Antibody; scFv Fragment (HPAB-0247-YC-S(P)) | ELISA, FC | Human scFv |
HPAB-0248-YC-S(P) | Human Anti-CCR2 Recombinant Antibody; scFv Fragment (HPAB-0248-YC-S(P)) | ELISA, FC | Human scFv |
HPAB-0249-YC-S(P) | Human Anti-CCR2 Recombinant Antibody; scFv Fragment (HPAB-0249-YC-S(P)) | ELISA, FC | Human scFv |
HPAB-0250-YC-S(P) | Human Anti-CCR2 Recombinant Antibody; scFv Fragment (HPAB-0250-YC-S(P)) | ELISA, FC | Human scFv |
HPAB-0251-YC-S(P) | Mouse Anti-CCR2 Recombinant Antibody (clone 1D9); scFv Fragment | Antagonist | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-444CQ | Afuco™ Anti-CCR2 ADCC Recombinant Antibody (Plozalizumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, Inhib | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-099CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.